{
 "companyname": "REXAHN PHARMACEUTICALS, INC.",
 "symbol": "RNN",
 "description": "Pharmaceutical Preparations",
 "quarters": [
  {
   "cik": "0001228627",
   "companyname": "REXAHN PHARMACEUTICALS, INC.",
   "entityid": 404623,
   "primaryexchange": "NYSE MKT",
   "primarysymbol": "RNN",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/2/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0001140361-15-039272",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -198523,
   "changeincurrentliabilities": 69255,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -40111,
   "cashfromfinancingactivities": 22325,
   "cashfrominvestingactivities": 6959889,
   "cashfromoperatingactivities": -4502473,
   "cfdepreciationamortization": -6839,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 7000000,
   "netchangeincash": 2479741,
   "totaladjustments": -475943,
   "ebit": -4658555,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -4026530,
   "interestexpense": 0,
   "netincome": -4026530,
   "netincomeapplicabletocommon": -4026530,
   "researchdevelopmentexpense": 3103807,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 1554748,
   "commonstock": 18086,
   "deferredcharges": null,
   "cashandcashequivalents": 12450387,
   "cashcashequivalentsandshortterminvestments": 21457056,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 30785,
   "othercurrentassets": null,
   "othercurrentliabilities": 1586229,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 110653,
   "retainedearnings": -102864709,
   "totalassets": 23074251,
   "totalcurrentassets": 22932813,
   "totalcurrentliabilities": 5368042,
   "totalliabilities": 5368042,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 17706209,
   "treasurystock": -128410
  },
  {
   "cik": "0001228627",
   "companyname": "REXAHN PHARMACEUTICALS, INC.",
   "entityid": 404623,
   "primaryexchange": "NYSE MKT",
   "primarysymbol": "RNN",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "8/7/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0001140361-15-030473",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -291311,
   "changeincurrentliabilities": 419269,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -4453,
   "cashfromfinancingactivities": 1008790,
   "cashfrominvestingactivities": 2635547,
   "cashfromoperatingactivities": -4402901,
   "cfdepreciationamortization": -8260,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 2640000,
   "netchangeincash": -758564,
   "totaladjustments": -1168741,
   "ebit": -4819940,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -3234160,
   "interestexpense": 0,
   "netincome": -3234160,
   "netincomeapplicabletocommon": -3234160,
   "researchdevelopmentexpense": 3235088,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 1584852,
   "commonstock": 18074,
   "deferredcharges": null,
   "cashandcashequivalents": 9970646,
   "cashcashequivalentsandshortterminvestments": 25984017,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 30785,
   "othercurrentassets": null,
   "othercurrentliabilities": 2209620,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": null,
   "propertyplantequipmentnet": 77841,
   "retainedearnings": -98838179,
   "totalassets": 27369877,
   "totalcurrentassets": 27261251,
   "totalcurrentliabilities": 5940928,
   "totalliabilities": 5940928,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 21428949,
   "treasurystock": -128410
  },
  {
   "cik": "0001228627",
   "companyname": "REXAHN PHARMACEUTICALS, INC.",
   "entityid": 404623,
   "primaryexchange": "NYSE MKT",
   "primarysymbol": "RNN",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/8/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0001140361-15-018528",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -260040,
   "changeincurrentliabilities": 290276,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -7935,
   "cashfromfinancingactivities": 705542,
   "cashfrominvestingactivities": 4236240,
   "cashfromoperatingactivities": -4038817,
   "cfdepreciationamortization": -8918,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 4244175,
   "netchangeincash": 902965,
   "totaladjustments": 232894,
   "ebit": -4417708,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -4271711,
   "interestexpense": 0,
   "netincome": -4271711,
   "netincomeapplicabletocommon": -4271711,
   "researchdevelopmentexpense": 2893008,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 1524700,
   "commonstock": 17932,
   "deferredcharges": null,
   "cashandcashequivalents": 10729210,
   "cashcashequivalentsandshortterminvestments": 29385031,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 25681,
   "othercurrentassets": null,
   "othercurrentliabilities": 3773135,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 79866,
   "retainedearnings": -95604019,
   "totalassets": 30481605,
   "totalcurrentassets": 30376058,
   "totalcurrentliabilities": 7103924,
   "totalliabilities": 7103924,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 23377681,
   "treasurystock": -128410
  }
 ]
}